文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症儿科与产科急症

儿童及年轻成人CRRT期间使用血管加压素与不良肾脏结局的关联

The Association Between Vasopressin and Adverse Kidney Outcomes in Children and Young Adults Requiring Vasopressors on Continuous Renal Replacement Therapy.
PubMed 文献 · Crit Care Explor · 2024-09-20
一句话结论在需要血管加压药的CRRT患儿及年轻成人中,使用血管加压素与90天主要不良肾脏事件(MAKE-90)风险升高相关(aOR 1.80),但早期启动可能有益。

WE-ROCK多中心回顾性队列的二次分析,纳入34个中心2015年1月1日至2021年12月31日期间因急性肾损伤和/或液体过负荷接受CRRT且需要血管加压药的25岁以下患者。1016例中665例(65%)在CRRT第一周需要血管加压药,其中248例(37%)使用血管加压素;473例(71%)发生MAKE-90,195例(29%)在28天内首次尝试即脱离CRRT。使用血管加压素与MAKE-90风险升高相关(aOR 1.80;95%CI 1.20-2.71;p=0.005),但与脱离CRRT成功无关;血管加压素组中,与早期启动相比,中期/晚期启动与MAKE-90风险升高相关(aOR 2.67;95%CI 1.17-6.11;p=0.02)。作者认为需前瞻性研究明确血管加压素使用的适当时机、剂量和亚人群。

要点

  • 在需要血管加压药的CRRT患儿及年轻成人中,使用血管加压素与MAKE-90风险升高相关(aOR 1.80;95%CI 1.20-2.71;p=0.005)。
  • 使用血管加压素与28天内首次尝试脱离CRRT成功无关。
  • 血管加压素组中,与早期(CRRT当天或之前)启动相比,中期(第1-2天)/晚期(第3-7天)启动与MAKE-90风险升高相关(aOR 2.67;95%CI 1.17-6.11;p=0.02)。
  • 665例需要血管加压药的患者中,248例(37%)使用血管加压素,473例(71%)发生MAKE-90。
  • 作者认为需前瞻性研究明确血管加压素使用的适当时机、剂量和亚人群。

适用人群与场景

  • 25岁以下、因急性肾损伤和/或液体过负荷接受CRRT且需要血管加压药的患者;来自34个中心的新生儿、心脏、PICU,时间范围为2015年1月1日至2021年12月31日。
  • 比较组为仅使用去甲肾上腺素/肾上腺素的患者。

诊断标准与关键阈值

  • MAKE-90定义为死亡、肾脏替代治疗依赖和/或CRRT启动后90天血清肌酐较基线升高>125%。
  • 血管加压素启动时机分类:早期为CRRT当天或之前(第0天及以前),中期为第1-2天,晚期为第3-7天。

研究设计与关键结果

  • WE-ROCK多中心回顾性队列研究的二次分析,纳入34个中心1016例患者;665例(65%)在CRRT第一周需要血管加压药,其中248例(37%)使用血管加压素。
  • 665例中473例(71%)发生MAKE-90,195例(29%)在28天内首次尝试即脱离CRRT。
  • 使用血管加压素与MAKE-90风险升高相关(aOR 1.80;95%CI 1.20-2.71;p=0.005),但与脱离CRRT成功无关。
  • 血管加压素组中,与早期启动相比,中期/晚期启动与MAKE-90风险升高相关(aOR 2.67;95%CI 1.17-6.11;p=0.02)。

证据类型、等级与局限

  • 证据类型:多中心回顾性队列研究的二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在需要血管加压药的CRRT患儿及年轻成人中,使用血管加压素与MAKE-90风险升高相关,但在使用者中早期启动似乎有益。
  • 作者认为,需前瞻性研究明确血管加压素使用的适当时机、剂量和亚人群。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Continuous renal replacement therapy (CRRT) and shock are both associated with high morbidity and mortality in the ICU. Adult data suggest renoprotective effects of vasopressin vs. catecholamines (norepinephrine and epinephrine). We aimed to determine whether vasopressin use during CRRT was associated with improved kidney outcomes in children and young adults.

DESIGN: Secondary analysis of Worldwide Exploration of Renal Replacement Outcomes Collaborative in Kidney Disease (WE-ROCK), a multicenter, retrospective cohort study.

SETTING: Neonatal, cardiac, PICUs at 34 centers internationally from January 1, 2015, to December 31, 2021.

PATIENTS/SUBJECTS: Patients younger than 25 years receiving CRRT for acute kidney injury and/or fluid overload and requiring vasopressors. Patients receiving vasopressin were compared with patients receiving only norepinephrine/epinephrine. The impact of timing of vasopressin relative to CRRT start was assessed by categorizing patients as: early (on or before day 0), intermediate (days 1-2), and late (days 3-7).

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: Of 1016 patients, 665 (65%) required vasopressors in the first week of CRRT. Of 665, 248 (37%) received vasopressin, 473 (71%) experienced Major Adverse Kidney Events at 90 days (MAKE-90) (death, renal replacement therapy dependence, and/or > 125% increase in serum creatinine from baseline 90 days from CRRT initiation), and 195 (29%) liberated from CRRT on the first attempt within 28 days. Receipt of vasopressin was associated with higher odds of MAKE-90 (adjusted odds ratio [aOR], 1.80; 95% CI, 1.20-2.71; p = 0.005) but not liberation success. In the vasopressin group, intermediate/late initiation was associated with higher odds of MAKE-90 (aOR, 2.67; 95% CI, 1.17-6.11; p = 0.02) compared with early initiation.

CONCLUSIONS: Nearly two-thirds of children and young adults receiving CRRT required vasopressors, including over one-third who received vasopressin. Receipt of vasopressin was associated with more MAKE-90, although earlier initiation in those who received it appears beneficial. Prospective studies are needed to understand the appropriate timing, dose, and subpopulation for use of vasopressin.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Hasson DC, Gist KM, Seo J, et al. The Association Between Vasopressin and Adverse Kidney Outcomes in Children and Young Adults Requiring Vasopressors on Continuous Renal Replacement Therapy. Crit Care Explor. 2024. PMID: 39318499. doi:10.1097/CCE.0000000000001156

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。